Consort Medical (LON:CSRT) said the impending launch of a generic Advair inhaler by Mylan (NSDQ:MYL) represents a significant opportunity for its Bespak drug delivery device unit, but analysts were less impressed after the FDA delayed its decision date for asthma therapy to March 28, 2017. That pushed CSRT shares down -1.9% to a $1.35 (941 pence) close yesterday on […]
Asthma
Smart inhaler maker raises $14.5M
Propeller Health is ready for big things, having just raised $14.5 million and hired an operations chief to lead a new San Francisco office.
Boston Scientific breathes easy with China win for Alair
Boston Scientific (NYSE:BSX) said the Chinese FDA approved its Alair bronchial thermoplasty system for treating patients with persistent asthma.
Boston Scientific hits 4-year high following asthma treatment trial results
From flu to fungi: Different asthmas, different pathways
Understanding asthma’s different pathways may allow individualized treatments.
Asthma: Boston Scientific wins new insurance codes for Alair system
Medical device industry giant Boston Scientific (NYSE:BSX) won insurance reimbursement codes for its latest star device, the Alair bronchial thermoplasty system for asthma treatment.
The Alair system delivers precise thermal energy to lung tissue via bronchoscope to reduce excessively smooth muscle, decreasing the airways’ ability to constrict.
Asthmapolis wins FDA clearance for new sensor and software | Regulatory Roundup
BSX’s Mahoney details outlook on up-and-coming businesses, including renal denervation and ICDs
Boston Scientific’s (NYSE:BSX) got a busy road ahead, with regulatory approvals and market launches in the works for products in some of its hottest business divisions.
Video: Illinois Rep. Roskam calls for action on the med-tech tax | MassDevice.com On Call
MASSDEVICE ON CALL — Rep. Peter Roskam (R-Ill.) dedicated his latest "Ask Peter" video to warning viewers about the impact the medical device tax could have on jobs in Illinois and asking viewers to make their voices heard through emails, calls and letters to his office.
Boston Scientific’s Alair asthma treatment gets a thumbs-up | Regulatory Roundup
Breast cancer: Ultrasound-guided surgery bests “blind” tumor removal | MassDevice.com On Call
MASSDEVICE ON CALL — Ultrasound-guided breast tumor removal proved "much more successful" than standard surgery in excising all cancerous tissue while leaving as much healthy tissue as possible, according to a report unveiled at the European Breast Cancer Conference last week.
Researchers expect their findings to reform the standard of care for palpable breast tumors, or those that can be felt, according to a press release.